Filing Flows › Health Care › NRX Pharmaceuticals (NRXP)
NRX Pharmaceuticals (NRXP) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · NRX Pharmaceuticals (NRXP) Q2 2026 earnings results →
Q2 2026 operating margin -590.8%
NRX Pharmaceuticals made $1.1M in Q2 2026: Therapy $871K, Procedures $230K. Operating margin -590.8%, net loss $16.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.1M in Q2 2026, up 3% from the previous quarter. Therapy was the largest line at 79% of revenue.
Operating costs exceeded revenue by $6.5M, an operating margin of -590.8%. The quarter ended with a net loss of $16.5M, wider than the previous quarter's $1.4M loss. Net interest and other expense of $10.0M was the main reason.
Operating cash flow was −$8.9M. Non-cash charges added back $71K of depreciation and amortization and $139K of share-based compensation. Working capital and other items added $7.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $1.1M | — | -590.8% | −$16.5M | −$8.9M |
| Q1 2026 | 10-Q | May 15, 2026 | $1.1M | — | -444.0% | −$1.4M | −$4.3M |
| Q4 2025 | 10-K | Mar 23, 2026 | $1.2M | — | -384.4% | $360K | −$3.7M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $242K | — | n/m | −$5.9M | −$2.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”, the “Company”, “we”, “us” or “our”) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiary, NeuroRx, Inc., (NeuroRx), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder (PTSD) and schizophrenia. NRx is additionally the founder and majority owner of HOPE Therapeutics, Inc. (HOPE), a medical services company that offers interventional psychiatry care to patients with treatment-resistant depression and PTSD with a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy.
In its own words, from its 10-K, filed Mar 23, 2026.
NRX Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -590.8% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NRXP NRX Pharmaceuticals | Q2 2026 | $1.1M | — | -590.8% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: NRX Pharmaceuticals 10-Q on SEC EDGAR · CIK 1719406 · Pharmaceutical Preparations
13F: who owns NRXP and who is buying
More on NRXP
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results